HighTide Therapeutics plans HK$225.72 million share placement at HK$2.28 each

• Hightide Therapeutics launched a placing of up to 99,000,000 new shares at HK$ 2.28 each under its general mandate.
• Deal size implies gross proceeds of about HK$ 225.72 million; net proceeds estimated at HK$ 223.07 million.
• Placing price reflects a 12.31% discount to the July 31 close of HK$ 2.6.
• New shares equal about 17.33% of existing share capital; about 14.77% on an enlarged basis.
• Proceeds earmarked mainly for HTD1801 commercialization in T2DM, expansion into new indications such as CKD, other R&D, working capital.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hightide Therapeutics Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260731-12265132), on July 31, 2026, and is solely responsible for the information contained therein.